Team
CEO
Enda Kenny, BSc, PhD, DIC
The Company is managed by Dr. Enda Kenny, an experienced pharma executive with a background in general management, regulatory affairs and R&D. He has held senior roles with Stryker Biotech, Inamed and has worked in the field of gastric peptide hormones for over 15 years. He has educational qualifications in biochemistry and microbiology.
Chief Business Officer
Lynn Sullivan, BA
Ms. Sullivan is a pioneering commercial leader in GLP-1 therapies, having led the launches of Ozempic®, Wegovy®, Saxenda®, and Rybelsus®—the first weekly, oral, and injectable GLP-1s for diabetes and obesity. With over 30 years of experience creating markets for novel mechanisms, she has helped establish entirely new treatment categories. Earlier in her career, she launched Prilosec® and Humira®, both breakthrough therapies that introduced new modes of action for GI-related diseases.
Board
Richard Warburg, BSc, PhD, JD
Dr. Warburg trained as a biochemist and subsequently qualified as a patent attorney. He is a General Partner of Scientia Ventures/New Ventures Funds and is a Director at the life science companies Cristcot, Verigraft, Drumroll and Smartech.
Jonathan Finn, BA, CFA
Mr. Finn is a Chartered Financial Analyst and a co-founder and General Partner of Scientia Ventures/New Ventures Funds. He is also EVP and Chief Investment Officer at Vantage Consulting Group and a Director at Solor Bioenergi AB, Verigraft AB and Atossa Therapeutics, Inc. (NASDAQ:ATOS).
Michael Forer, BS, LLB
Mr. Forer is a co-founder of ADC Therapeutics (NYSE:ADCT), Vice Chairman of GH Research (NASDAQ:GHRS) and a co-founder and Partner at Rosetta Capital, a UK-based life science venture capital investor. Mr. Forer is called to the Bar in the Province of Ontario, Canada.